medigraphic.com
ISSN 1995-9494 (Electronic)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"

2022, Number 4

<< Back Next >>

Acta Med Cent 2022; 16 (4)

Estimation of reference values of the enzyme Myeloperoxidase: biomarker of clinical deterioration in patients with COVID-19

Ruiz MAA, González ML, Carvajal CE, De Armas FI, Valdés UJR, Machín PE

Language: Spanish
References: 30
Page: 614-625
PDF size: 585.87 Kb.


ABSTRACT

Introduction: the COVID-19 pandemic has come to undermine human physical and spiritual health. Many evidences point to the role of neutrophil extracellular traps and their combat weapon: Myeloperoxidase enzyme, as part of the immune response against this lethal infection.
Objective: to determine the reference values of the enzyme myeloperoxidase, biomarker for the evaluation of clinical deterioration in patients with Covid-19.
Methods: in the Department of Biomedical Research of the Direction of Science and Technological Innovation, University of Medical Sciences of Villa Clara, the determination of the enzyme Myeloperoxidase was implemented, its analytical validation and the estimation of reference values in a supposedly healthy population were carried out. For this purpose, a quantitative, transversal and descriptive research protocol was carried out involving patients from the Provincial Blood Bank. Blood plasma was used as a biological sample and myeloperoxidase activity was estimated. Interfractal limits were determined between 2.5 and 97.5 percentiles.
Results: the analytical parameters of linearity, precision and trueness of the method corresponded to the requirements of international standards. The reference values for the healthy population studied were in the range between 110-960 U/L.
Conclusions: the reference values are related to other reports and contribute to the evaluation of patient status and as a prognostic biomarker of severity of the patient affected by COVID-19.


REFERENCES

  1. Organización Mundial de la Salud [Internet]. Ginebra: OMS; 2020 [actualizado 27/04/2020; citado 19/05/2022]. COVID-19: cronología de la actuación de la OMS; [aprox. 5 patallas]. Disponible en: https://www.who.int/es/news/item/27-04-2020-who-timeline---covid-191.

  2. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet [Internet]. 2020 [citado 19/05/2022];395(10229):1033-1034. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/fulltext2. . https://doi.org/10.1016/S0140-6736(20)30628-0

  3. Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr [Internet]. 2020 [citado 19/05/2022];14(4):407-412. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165108/3. . https://doi.org/10.1016/j.dsx.2020.04.020

  4. Denys GA, Devoe NC, Gudis P, May M, Allen RC, Stephens JT Jr. Mechanism of microbicidal action of E-101 solution, a myeloperoxidase-mediated antimicrobial, and its oxidative products. Infect Immun [Internet]. 2019 [citado 19/05/2022];87(7):e00261-19. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589053/4. . https://doi.org/10.1128/IAI.00261-19

  5. Wilkerson RG, Adler JD, Shah NG, Brown R. Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19. Am J Emerg Med [Internet]. 2020 [citado 19/05/2022];38(10):2243.e5-2243.e6. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243756/5. . https://doi.org/10.1016/j.ajem.2020.05.044

  6. Wang J, Li Q, Yin Y, Zhang Y, Cao Y, Lin X, et al. Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19. Front Immunol [Internet]. 2020 [citado 19/05/2022];11:2063. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/6. . https://doi.org/10.3389/fimmu.2020.02063

  7. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19 [Internet]. medRxiv [Preprint]. 2020 [citado 19/05/2022]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276989/7. . https://doi.org/10.1101/2020.04.09.20059626

  8. Oficina Nacional de Normalización. Norma Cubana (NC) TS 368: 2010. Guía para la validación de métodos de ensayos químicos para alimentos. La Habana: Oficina Nacional de Normalización; 2010.

  9. Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos. Regulación D 20-17 Buenas Prácticas de Fabricación para Diagnosticadores [Internet]. La Habana: CECMED; 2017 [citado 19/05/2022]. Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/Reglamentacion/res.no_.166.regul_.bpfdiagnosticadores.pdf9.

  10. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Bethesda: NIH; 2016 [citado 19/05/2022]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK326791/pdf/Bookshelf_ NBK326791.pdf10.

  11. International Medical Device Regulators Forum. Principles of Labelling for Medical Devices and IVD Medical Devices [Internet]. Australia: IMDRF; 2019 [citado 19/05/2022]. Disponible en: https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-190321-pl-md-ivd.pdf11.

  12. Organización Internacional de Normalización [Internet]. Ginebra: OIN; 2019 [citado 19/05/2022]. ISO 35001:2019(es) Gestión del riesgo biológico en laboratorios y otras organizaciones relacionadas; [aprox. 14 pantallas]. Disponible en: https://www.iso.org/obp/ui#iso:std:iso:35001:ed-1:v1:es12.

  13. Organización Internacional de Normalización [Internet]. Ginebra: OIN; 2020 [citado 19/05/2022]. ISO 15190:2020 Laboratorios clínicos - Requisitos de seguridad; [aprox. 11 pantallas]. Disponible en: https://www.iso.org/obp/ui/#iso:std:iso:15190:ed-2:v1:es13.

  14. Organización Internacional de Normalización [Internet]. Ginebra: OIN; 2019 [citado 19/05/2022]. ISO/IEC Guide 63:2019(en). Guide to the development and inclusion of aspects of safety in International Standards for medical devices; [aprox. 8 pantallas]. Disponible en: https://www.iso.org/obp/ui#iso:std:iso-iec:guide:63:ed-3:v1:en14.

  15. Organización Internacional de Normalización [Internet]. Ginebra: OIN; 2017 [citado 10/05/2022]. ISO/TS 20658:2017(en) Medical laboratories - Requirements for collection, transport, receipt, and handling of samples; [aprox. 7 pantallas]. Disponible en: https://www.iso.org/obp/ui#iso:std:iso:ts:20658:ed-1:v1:en15.

  16. Graff G, Gamache DA, Brady MT, Spellman JM, Yanni JM. Improved myeloperoxidase assay for quantitation of neutrophil influx in a rat model of endotoxin-induced uveitis. J Pharmacol Toxicol Methods [Internet]. 1998 [citado 19/05/2022];39(3):169-78. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9741392/16. . https://doi.org/10.1016/s1056-8719(98)00023-9

  17. Prada E, Blazquez R, Gutiérrez-Bassini G, Morancho J, Jou JM, Ramón F, et al. Control interno de la calidad vs control externo de la calidad. Rev Lab Clín [Internet]. 2016 [citado 19/05/2022];9(2):54-59. Disponible en: https://www.elsevier.es/es-revista-revista-del-laboratorio-clinico-282-articulo-control-interno-calidad-vs-control-S188840081630007117. . https://orcid.org/10.1016/j.labcli.2016.04.003

  18. Horowitz G. Reference Intervals: Practical Aspects. EJIFCC [Internet]. 2008 [citado 19/05/2022];19(2):95-105. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975204/18.

  19. Organización Internacional de Normalización [Internet]. Ginebra: OIN; 2017 [citado 19/05/2022]. ISO/IEC 17025:2017(es) Requisitos generales para la competencia de los laboratorios de ensayo y calibración; [aprox. 7 pantallas]. Disponible en: https://dgn.isolutions.iso.org/obp/ui#iso:std:iso-iec:17025:ed-3:v2:es19.

  20. EUROLAB [Internet]. Estambul: EUROLAB; 2022 [citado 19/05/2022]. Dispositivos médicos de diagnóstico in vitro ISO 23640: evaluación de la estabilidad de los reactivos de diagnóstico in vitro; [aprox. 2 pantallas]. Disponible en: https://www.laboratuar.com/es/testler/medikal-cihaz-testleri/iso-23640-in-vitro-diagnostik-tibbi-cihazlar---in-vitro-diagnostik-reaktiflerin-stabilitesinin-degerlendirilmesi/20.

  21. Organización Internacional de Normalización [Internet]. Ginebra: OIN; 2016 [citado 19/05/2022]. ISO 13485:2016(en) Medical devices - Quality management systems - Requirements for regulatory purposes; [aprox. 50 pantallas]. Disponible en: https://www.iso.org/obp/ui#iso:std:iso:13485:ed-3:v1:en21.

  22. Hrynkiewicz R, Bebnowska D, Niedzwiedzka-Rystwej P. Myeloperoxidase and lysozymes as a pivotal hallmark of immunity status in rabbits. Animals (Basel) [Internet]. 2020 [citado 19/05/2022];10(9):1581. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552177/22. . https://doi.org/10.3390/ani10091581

  23. Schrijver IT, Kemperman H, Roest M, Kesecioglu J, de Lange DW. Myeloperoxidase can differentiate between sepsis and non-infectious SIRS and predicts mortality in intensive care patients with SIRS. Intensive Care Med Exp [Internet]. 2017 [citado 19/05/2022];5(1):43. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602808/23. . https://doi.org/10.1186/s40635-017-0157-y

  24. Ege S, Bademkiran MH, Peker N, Erdem S, Bagli I, Köçeroglu R, et al. Evaluation of catalase, myeloperoxidase and ferroxidase values in pregnant women with hyperemesis gravidarum. Ginekol Pol [Internet]. 2019 [citado 19/05/2022];90(11):651-655. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31802466/24. . https://doi.org/10.5603/GP.2019.0110

  25. Yapur VM, Bustos MF, Di Carlo MB, López Mingorance FN, Vázquez Blanco M, Negri GA. Niveles séricos de ceruloplasmina y mieloperoxidasa en pacientes con enfermedad coronaria crónica. Acta Bioquím Clín Latinoam [Internet]. 2013 [citado 19/05/2022];47(1):53-59. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-2957201300010000825.

  26. Siraki AG. The many roles of myeloperoxidase: From inflammation and immunity to biomarkers, drug metabolism and drug discovery. Redox Biol [Internet]. 2021 [citado 19/05/2022];46:102109. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403760/26. . https://doi.org/10.1016/j.redox.2021.102109

  27. Zhang Y, Han K, Du C, Li R, Liu J, Zeng H, et al. Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients. Crit Care [Internet]. 2021 [citado 19/05/2022];25(1):51. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868871/27. . https://doi.org/10.1186/s13054-021-03482-z

  28. Zuo Y, Zuo M, Yalavarthi S, Gockman K, Madison J, Shi H, et al. Neutrophil extracellular traps and thrombosis in COVID-19. J Thromb Thrombolysis [Internet]. 2021 [citado 19/05/2022];51(2):446-53. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642240/28. . https://doi.org/10.1007/s11239-020-02324-z

  29. Middleton EA, He XY, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood [Internet]. 2020 [citado 19/05/2022];136(10):1169-1179. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472714/29. . https://doi.org/10.1182/blood.2020007008

  30. Algeciras-Schimnich A. Intervalos de Referencia: conceptos, interpretación y protocolos de verificación recomendados por CLSI EP28-A3c [Internet]. Washington: American Association for Clinical Chemistry; 2020 [citado 19/05/2022]. Disponible en: https://www.aacc.org/advocacy-and-outreach/global-lab-quality-initiative/webinars-en-espanol/2020/intervalos-de-referencia30.




2020     |     www.medigraphic.com